In APL, MYC cooperates with PML-RARα to accelerate the development of leukemia [43], while in AML, MYC protein expression is a poor prognostic factor, particularly in patients with high risk of relapse [44,45]. The gene discussed is MYC; the disease is acute myeloid leukemia.